Dako Partners With General Data To Increase Patient Safety

Glostrup, Denmark, Jan 28, 2008 - (ABN Newswire) - Dako enters a Supply and Distribution Agreement with General Data Company Inc., becoming a global provider of a unique patient tissue sample identification and tracking system for anatomic pathology laboratories.

Dako, a global provider of solutions for tissue-based cancer diagnostics, becomes supplier of bar-code labeling, identification and data collection products from General Data Inc.

The agreement is part of Dako's strategy to deliver full, world-class diagnostic solutions providing fast and accurate answers for cancer patients and doctors making vital decisions for treatment. Bar-code labeling and durable printing solutions to secure patient ID from tissue sample to diagnosis are tools to reduce manual transcription steps and streamline laboratory processes.

"Patient safety is a challenge to every hospital and health-care system. Keeping track of the patient's identity through all laboratory processes is a critical step forward. We believe General Data to have the strongest product-portfolio in the area of True Positive ID and that it optimally complements Dako's portfolio of know-how, instruments, reagents and software solutions for cancer diagnostics. We see this, when considered in combination with our global distribution-reach, as a very fruitful partnership," says Patrik Dahlén, CEO and President of the Dako Group.

Bar-code based identification of patients, scanning and data collection systems increase patient safety by reducing identification errors in medication administration, transfusion, specimen collection, patient charging, and point-of-care testing. The FDA estimates that implementation of a bar-code identification and data management system can reduce errors by over 80% and save healthcare providers more than 83 billion dollars over the next 20 years.

"General Data is proud to enter this partnership with Dako bringing innovative bar-code technologies to the lab for effective, reliable identification and tracking of tissue samples," says Pete Wenzel, CEO and President of General Data. "Integration of our ID/Positive and StainerShield product solutions with the Dako Link product, Dako's global customer base and drive for quality is a perfect fit. Our focus is on helping healthcare providers deliver higher levels of patient safety and care, and our partnership with Dako will speed that process on a global basis."

Dako's distribution rights for General Data's products cover all healthcare markets globally - and Dako becomes exclusive supplier outside the US.

About Dako Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and operating in more than 70 countries, Dako covers essentially all of the global anatomic pathology markets. Dako is owned by a private equity fund, EQT. www.dako.com

About General Data Inc. General Data Company Inc., is recognized as a premier provider of innovative bar-code identification and automated data collection products and solutions that enable organizations to streamline workflow, error-proof processes, optimize management of critical data, and improve the accuracy, productivity and performance of business-processes. Founded in 1981, General Data is a privately held company with headquarters in Cincinnati, Ohio USA. More information on General Data's products and solutions can be found at www.general-data.com

Media contacts:

Dako Denmark A/S Anne Thommesen, Corporate Communications, +45 40 63 95 93

General Data Company, Inc. Ralph Moher, VP Marketing +1 800 733 5252



LINK: http://hugin.info/136715/R/1185658/237384.pdf

Copyright © Hugin AS 2008. All rights reserved.

Dako Denmark A/S

http://www.dako.com

Stock Identifier: CSE.DAKO